Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30% Respectively in Fourth Quarter 2022 vs Third Quarter 2022 Company Reaffirms Expected Full Year...
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the market close on Wednesday, March...
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”)...
FDA Agrees to Extended Milestones for Long-Term Twirla ® Safety Study New Publication Supports Eventual Pursuit of AG200-15 Extended Regimen Development Program PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today provided...
PRINCETON, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series C Preferred Stock, par value $0.0001 per share, for...
Fourth Quarter 2022 Twirla Factory Sales Expected to Increase Approximately 30% from Third Quarter 2022 Full Year 2022 Factory Sales Expected to Increase Approximately 232% from Full Year 2021 Full Year 2023 Net Revenue Expected to be in Range of $25-$30 Million PRINCETON, N.J., Jan....
PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022....
Net Revenue Increased 43% from Second Quarter 2022 Largest Quarter-over-Quarter Increase in Net Revenue Achieved by Agile Non-Retail Channel Twirla Cycles Grew 361% from Second Quarter 2022 Company Expects Business Plan Can Deliver Additional Growth in the Fourth Quarter of 2022 and in 2023...
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022....
Appointment of Amy Welsh to Chief Commercial Officer Prioritizes Commercial Growth Company Streamlines Leadership Team to Align with Plan to Grow Twirla ® James Tursi, M.D. Resigns from Board of Directors PRINCETON, N.J., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
